3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Lung Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
5
fludarabine
2
enfortumab vedotin
2
darolutamide
2
atezolizumab
2
aldesleukin
2
Riluzole
2
Nivolumab
2
Mitomycin
2
Fecal Microbiota Transplantation
2
Cyclophosphamide
2
vedolizumab
1
relatlimab
1
prednylidene
1
olaparib
1
lenvatinib
1
deltacortene
1
cabozantinib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tadalafil
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Rivaroxaban
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Prednisone
1
Practice Guidelines as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urogenital Neoplasms
×
Pregnancy Tests
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled